In a renal‑transplant recipient without a history of ulcerative colitis, how should CMV colitis be evaluated and managed, including optimal colonoscopic biopsy sites and antiviral therapy?

CMV Colitis in Renal Transplant Recipients Without UC History

In a renal transplant recipient without ulcerative colitis presenting with suspected CMV colitis, perform colonoscopy with biopsies from any visible mucosal lesions and treat with intravenous ganciclovir for serious disease or oral valganciclovir for mild disease, continuing until CMV is undetectable by plasma PCR. 1

Diagnostic Approach

Endoscopic Evaluation

When CMV colitis is suspected in your renal transplant patient, colonoscopy is the definitive diagnostic procedure. Target your biopsies strategically:

• Biopsy all visible mucosal lesions - ulcers and erosions are the most common colonoscopic findings in CMV colitis, present in 43.1% and 37.3% of cases respectively 2
• Multiple biopsies from affected areas are essential, as CMV detection requires tissue confirmation
• Fresh bleeding per rectum and the presence of both ulcers and erosions are significantly associated with CMV colitis 2

Laboratory Confirmation

The diagnosis requires a two-pronged approach:

Blood testing:

• Obtain CMV quantitative PCR (viral load) from plasma 1
• Monitor weekly during active disease 1

Tissue diagnosis (definitive):

• Histopathology showing CMV in gastrointestinal tissue by culture, immunohistochemical analysis, or in situ hybridization 3
• Typical CMV inclusions on morphologic examination are sufficient evidence 3

Critical caveat: CMV colitis can occur with undetectable serum viral load 4. In one documented case, a transplant recipient had biopsy-proven CMV colitis despite negative serum PCR. Therefore, if clinical suspicion is high (diarrhea, abdominal pain, GI bleeding), proceed with colonoscopy and biopsy even if blood CMV PCR is negative 4.

Treatment Algorithm

Initial Antiviral Therapy

For serious/tissue-invasive CMV disease (which includes most CMV colitis):

• Start intravenous ganciclovir immediately 1
• This is a strong recommendation (1D grade) from KDIGO guidelines

For mild CMV colitis with minimal symptoms:

• Either IV ganciclovir OR oral valganciclovir is acceptable in adults 1
• Pediatric patients must receive IV ganciclovir regardless of severity 1

Immunosuppression Management

Reduce immunosuppressive medications in two scenarios:

1. Life-threatening CMV disease 1
2. CMV disease persisting despite antiviral treatment 1

Typical reductions involve:

• Mycophenolate mofetil minimization or withdrawal 5
• Calcineurin inhibitor dose reduction 5

Monitor graft function closely during CMV disease, as reduction in immunosuppression risks rejection 1

Duration and Monitoring

• Continue antiviral therapy until CMV is undetectable by plasma PCR or pp65 antigenemia 1
• Monitor CMV viral load weekly during treatment 1
• Do not stop treatment based on clinical improvement alone; wait for virologic clearance

Resistant or Refractory Disease

If CMV persists despite first-line therapy:

• Maribavir is recommended as second-line therapy for resistant/refractory CMV 6
• Foscarnet is an alternative, particularly for CNS disease, retinitis, or very high viral loads 6, 7
• Obtain resistance testing (UL97 and UL54 mutations) in patients who develop CMV disease despite prophylaxis 3

Common Pitfalls

1. Don't rely solely on serum CMV PCR - tissue diagnosis is gold standard, and colitis can occur with negative viremia 4

2. Don't delay colonoscopy - the frequency of CMV colitis in renal transplant recipients with lower GI bleeding is 22.1% 2

3. Don't stop antivirals when symptoms improve - continue until virologic clearance to prevent relapse 1

4. Don't forget to reduce immunosuppression in severe or persistent cases - this is as important as antiviral therapy 1

5. Monitor for acute rejection when reducing immunosuppression, as this is a real risk during CMV disease management 5

Clinical Presentation Clues

The most common presenting features in renal transplant recipients with CMV colitis are:

• Fresh bleeding per rectum (76.8%) 2
• Abdominal pain 5
• Diarrhea 5
• Fever 5
• Weight loss and anorexia 4

These symptoms typically occur in the first few months post-transplant, though timing varies with prophylaxis strategies 3.